Technical Analysis for BMRN - BioMarin Pharmaceutical Inc.

Grade Last Price % Change Price Change
D 63.93 -0.64% -0.41
BMRN closed down 0.64 percent on Friday, February 7, 2025, on 63 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: Feb 20
*** please verify all earnings dates ***
6 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Bearish Engulfing Bearish 0.00%
Stochastic Reached Overbought Strength 0.00%
Weak + Overbought Other 0.00%
Outside Day Range Expansion 0.00%
Weak, Overbought and Reversal Signs Reversal 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength -0.64%
Crossed Above 20 DMA Bullish -0.40%
Gapped Down Weakness 1.69%

   Recent Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BioMarin Pharmaceutical Inc. Description

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company's commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It also develops Vimizim, an enzyme replacement therapy that is in phase III clinical stage for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; BMN-673, a clinical Phase I/II trial product for the treatment of cancer; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of BH4 in Kuvan for PKU and for other indications, and PEG-PAL. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Autoimmune Disease Treatment Of Cancer Drug Discovery Rare Diseases Virotherapy Metabolic Disease Genetic Diseases Genzyme Inborn Errors Of Metabolism Enzyme Replacement Therapy Lysosomal Storage Disorder Pompe Disease Mucopolysaccharidosis Achondroplasia Glycogen Storage Disorder Iduronidase Intellectual Disability Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Pharmaceutical Wholesalers Phenylketonuria Pku

Is BMRN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 94.85
52 Week Low 60.63
Average Volume 1,520,057
200-Day Moving Average 75.28
50-Day Moving Average 64.96
20-Day Moving Average 63.23
10-Day Moving Average 63.35
Average True Range 1.52
RSI (14) 49.75
ADX 12.92
+DI 20.08
-DI 19.02
Chandelier Exit (Long, 3 ATRs) 65.14
Chandelier Exit (Short, 3 ATRs) 65.19
Upper Bollinger Bands 66.46
Lower Bollinger Band 59.99
Percent B (%b) 0.61
BandWidth 10.24
MACD Line -0.42
MACD Signal Line -0.68
MACD Histogram 0.2583
Fundamentals Value
Market Cap 12.18 Billion
Num Shares 191 Million
EPS 1.65
Price-to-Earnings (P/E) Ratio 38.75
Price-to-Sales 4.45
Price-to-Book 2.25
PEG Ratio 0.40
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 65.75
Resistance 3 (R3) 65.91 65.46 65.45
Resistance 2 (R2) 65.46 65.00 65.38 65.35
Resistance 1 (R1) 64.70 64.71 64.47 64.54 65.25
Pivot Point 64.25 64.25 64.14 64.17 64.25
Support 1 (S1) 63.48 63.78 63.26 63.32 62.61
Support 2 (S2) 63.03 63.50 62.95 62.51
Support 3 (S3) 62.27 63.03 62.41
Support 4 (S4) 62.11